Sulfonamide Derivatives for Selective Alpha4beta7 Integrin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current α4 integrin inhibitors have limitations in selectivity, efficacy, and duration of action, particularly in targeting α4β7 integrin-dependent inflammatory diseases, with existing compounds often showing low effect on α4β1 but high effect on α4β7, and lacking long-acting and safe oral administration profiles.
Innovation Solution
Development of sulfonamide derivatives with a specific chemical structure containing a sulfonamide group and a phenyl group with an acylamino substituent, which exhibit high α4β7 integrin inhibitory activity in whole human blood, providing selectivity, safety, and long-acting oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phenylalanine derivatives with existing structures are used, then α4 integrin inhibitory activity is achieved, but selectivity between α4β1 and α4β7 is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions of the phenylalanine derivative structure. The R1 and R2 substituents on the phenyl ring, along with the R3-R6 side chain substituents, are carefully selected to create localized chemical properties that enhance α4β7 selectivity while maintaining overall structural feasibility for drug development.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halogen, alkyl, alkoxy, nitro, cyano groups) at different positions of the phenylalanine core structure. These parameter modifications optimize the balance between α4β7 inhibitory activity and α4β1 selectivity, allowing tuning of the compound's biological profile without completely redesigning the molecular framework.
2Duration of action of moving object
If existing α4 integrin inhibitors are administered orally, then convenience is improved, but duration of action is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying physical and chemical properties of the phenylalanine derivatives, including molecular weight, lipophilicity (through alkyl and alkoxy substituents), and metabolic stability (through halogen and aromatic substituents). These parameter optimizations enable the compounds to achieve both oral bioavailability and extended duration of action by resisting metabolic degradation while maintaining membrane permeability.
3Reliability
If existing α4 integrin inhibitors are used, then therapeutic effect is achieved, but safety profile is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific bioisosteric substituents and electron-withdrawing groups (halogens, nitro, cyano) at strategic positions that enhance metabolic stability and reduce off-target effects. These localized structural modifications improve the safety profile by preventing metabolic activation to toxic intermediates while maintaining therapeutic activity at lower doses.
4Reliability
If existing α4 integrin inhibitors are used, then α4β7 inhibitory activity is achieved, but effect on α4β1 is not sufficiently selective
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions of the phenylalanine derivative structure. The R1 and R2 substituents on the phenyl ring, along with the R3-R6 side chain substituents, are carefully selected to create localized chemical properties that enhance α4β7 selectivity while maintaining overall structural feasibility for drug development.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halogen, alkyl, alkoxy, nitro, cyano groups) at different positions of the phenylalanine core structure. These parameter modifications optimize the balance between α4β7 inhibitory activity and α4β1 selectivity, allowing tuning of the compound's biological profile without completely redesigning the molecular framework.
Data Source
AI summary
Provided is a compound having α4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification.